NeuroVigil, Inc., a company based in San Diego, has announced that is has formed a multi-year alliance with a large Pharmaceutical Company, which plans to deploy the iBrain technology in its pharmaceutical research.
The company also announced that it has separately created an alliance with the University of Basel, one of Europe's leading biomedical research universities, to specifically tackle Rett Syndrome, a lethal neurodevelopmental disorder that affects girls almost exclusively.
NeuroVigil's innovative proprietary suite of software algorithms and portable brain activity monitors was launched commercially in 2009 and is now a prevailing model for early Central Nervous System (CNS) Pharma research.
The commercial agreement, five years in the making, is a win-win partnership for both NeuroVigil and the pharmaceutical company as it will greatly expand the latter's research and development capabilities by gaining access to high-resolution and high-throughput data - automated analysis of a variety of substances, including chemicals and genes - while augmenting NeuroVigil's exclusive biomarker databases.
NeuroVigil will retain all rights to its data and any biomarkers discovered by either party and will not advise the pharmaceutical company on the pharmacological applications of its compounds.
Dr. Philip Low, Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of NeuroVigil notes that the uncapped agreement is unrestricted and both parties remain free to collaborate with other parties. "This new collaboration heralds an advancement for both companies - to discover and promote innovative methods to monitor disease and ultimately improve human health."
Source:University of Basel
No comments:
Post a Comment